Work Here?
Work Here?
Work Here?
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Seattle, Washington
Founded
2003
Company Does Not Provide H1B Sponsorship
NanoString Technologies focuses on spatial biology and molecular profiling, providing tools for researchers and clinicians to study gene and protein expression in tissue architecture. Their main products, like the GeoMx Digital Spatial Profiler and the nCounter Analysis System, help clients in drug development and cancer research by offering insights into how cells interact in their environments. Unlike competitors, NanoString combines proprietary instruments with consumables and data analysis services, creating a comprehensive solution for life sciences. The company's goal is to enhance scientific discovery and improve human health through high-resolution biological insights.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$1230.3M
Above
Industry Average
Funded Over
12 Rounds
Health Insurance
Paid Vacation
Paid Holidays
Performance Bonus
Company Equity
Growth Comes From InnovationEconomic growth can really come from only two sources: a larger pool of workers and/or resources or a more efficient use of available resources.With limited natural resources and declining demography, the first source of growth is increasingly unlikely to play a big role in Western economies, or in China for that matter. So growth has to come from better use of resources. And a key way to do so is through improved technology.A truck is more efficient than a horse, an excavator is more efficient than a man with a shovel, and a nuclear power plant is more efficient than burning wood or coal. More recently, technology has also started to improve intellectual professions with the rise of computers, the Internet, smartphones, software, and AI.Investing In TechnologyAny investment strategy prioritizing “tech” has probably outperformed the broader markets since the 1990s.The few wise enough investors that held on for decades to stocks of Apple, Amazon, or Tesla have likely seen returns in the 10x, 100x, or even 1000x. Today is no different.However, the most likely to grow exponentially are stocks that are just at the beginning of their journey, more than the established tech giants.So, in this article, we will explore tech companies still at an earlier stage, with large growth potential, a very long runway, and large growing markets in which to expand. We will also cover more than purely software stocks, as technological innovation also concerns hardware.10 Technology Stocks Poised for Future Growth(This list is by nature subjective and does not constitute investment advice).1
NEW YORK - The US District Court for the District of Delaware today granted 10x Genomics a permanent injunction in its patent infringement suit against NanoString Technologies (now a part of Bruker's spatial biology group).
Bruker has acquired NanoString Technologies for approximately $393 million in cash and assumed liabilities, following NanoString's bankruptcy. Bruker has formed a new division, the Bruker Spatial Biology Group, which includes NanoString, Canopy Biosciences, and Acuity Spatial Genomics. The division will maintain its original locations to avoid disruptions. Mark Munch and Todd Garland discuss Bruker's spatial biology strategy and future plans for the acquired technologies.
BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany GmbH by invalidating European Patent No. 2794928B1 (the “928 Patent”) in Germany (case 3 Ni 20/22). NanoString is now a Bruker business following Bruker’s asset acquisition of the businesses of NanoString Technologies, Inc on May 6th, 2024. The 928 Patent has been asserted by 10x Genomics against NanoString in patent infringement cases in Germany and before the European Unified Patent Court (UPC) involving NanoString’s CosMx Spatial Molecular Imager (SMI) products for RNA detection. The Federal Patent Court ruled that the German part of the 928 Patent is invalid. “NanoString has consistently maintained that the patents being asserted by 10x Genomics against NanoString’s CosMx SMI products are invalid
Tech Moves covers notable hires, promotions and personnel changes in the Pacific NW tech community. Submissions: [email protected] Gray. (LinkedIn Photo)Brad Gray is stepping down from NanoString after 14 years leading the Seattle biotech company as CEO.NanoString this week completed its acquisition to life sciences research and diagnostic giant Bruker, which bought the company’s assets for approximately $392.6 million in cash after NanoString entered a bankruptcy process earlier this year.“We have found in Bruker a wonderful home for the enterprise so many people worked so hard to build,” Gray wrote in a LinkedIn post. “I know our customers will be well cared for, and my colleagues will continue our mission to Map the Universe of Biology.”NanoString CFO Tom Bailey is also departing the company.Most of NanoString’s other senior leaders are staying onboard under its new owner, according to a NanoString spokesperson, including Chief Scientific Officer Joe Beechem.NanoString said in February it was exploring a potential sale following its loss in a patent infringement case late last year against 10X Genomics, which accused NanoString of infringing on seven patents related to NanoString’s GeoMx Digital Spatial Profiler that analyzes RNA and protein.Founded in 2003, NanoString spun out of the Institute for Systems Biology and went public in 2013.Before joining NanoString in 2010, Gray was a vice president at Genzyme Genetics, and also spent four years at McKinsey & Company.Other key personnel changes across Pacific Northwest tech:Temporal co-founders Samar Abbas (left) and Maxim Fateev. (Temporal Photo)— The co-founders of Temporal, a Seattle startup that helps companies write and run cloud applications, are swapping positions.Samar Abbas, who was previously CTO, is now CEO. Maxim Fateev, who was CEO, is now CTO.“This change is strategic, meant to leverage our founders’ unique strengths,” the company said on LinkedIn.Abbas and Fateev previously worked together at Uber and helped build an internal open-source orchestration engine called Cadence
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Seattle, Washington
Founded
2003
Find jobs on Simplify and start your career today